Integra LifeSciences (IART)
(Delayed Data from NSDQ)
$31.42 USD
+0.05 (0.16%)
Updated Jul 24, 2024 04:00 PM ET
3-Hold of 5 3
A Value F Growth F Momentum D VGM
Integra LifeSciences (IART) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$33.67 | $50.00 | $25.00 | 7.16% |
Price Target
Based on short-term price targets offered by nine analysts, the average price target for Integra LifeSciences comes to $33.67. The forecasts range from a low of $25.00 to a high of $50.00. The average price target represents an increase of 7.16% from the last closing price of $31.42.
Analyst Price Targets (9 )
Broker Rating
Integra LifeSciences currently has an average brokerage recommendation (ABR) of 2.89 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 12 brokerage firms. The current ABR compares to an ABR of 2.89 a month ago based on 12 recommendations.
Of the 12 recommendations deriving the current ABR, two are Strong Buy and one is Buy. Strong Buy and Buy respectively account for 16.67% and 8.33% of all recommendations. A month ago, Strong Buy made up 16.67%, while Buy represented 8.33%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/IART.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 2 | 4 |
Buy | 1 | 1 | 1 | 1 | 1 |
Hold | 6 | 6 | 6 | 6 | 4 |
Sell | 2 | 2 | 2 | 2 | 2 |
Strong Sell | 1 | 1 | 1 | 1 | 1 |
ABR | 2.89 | 2.89 | 2.89 | 2.89 | 2.56 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/15/2024 | Not Identified | Not Identified | Hold | Hold |
7/10/2024 | Not Identified | Not Identified | Hold | Hold |
5/7/2024 | Truist Securities | Richard Newitter | Hold | Hold |
5/7/2024 | Wells Fargo Securities | Vikramjeet S Chopra | Strong Buy | Hold |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Hold |
5/6/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
4/25/2024 | C.L. King & Associates | Kristen M Stewart | Moderate Buy | Moderate Buy |
2/29/2024 | JMP Securities | David L Turkaly | Strong Buy | Strong Buy |
1/2/2024 | BTIG | Ryan Zimmerman | Not Available | Hold |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 2.89 |
ABR (Last week) | 2.89 |
# of Recs in ABR | 12 |
Average Target Price | $33.67 |
LT Growth Rate | 9.20% |
Industry | Medical - Instruments |
Industry Rank by ABR | 103 of 252 |
Current Quarter EPS Est: | 0.62 |